Kite Pharma... CART19, CLL and DLBCL - CLL Support
Kite Pharma... CART19, CLL and DLBCL
You need to be a member of this community to see this post.
Read more about...
2 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Axi-Cel (anti-CD19 CAR T-cell therapy FMC63-28Z) Induces Durable Remissions in Relapsed CLL, B-Cell Lymphoma
Patients with relapsed chronic lymphocytic leukemia (CLL) and B-cell lymphoma who received the...
More CAR-T: Looking Back to Go Forward in CAR-T Cell Therapy in R/R CLL
Long-term data from a phase 1 study investigating anti-CD19 chimeric antigen receptor (CAR) T-cell...
An Early Look at When CAR-T Therapy Fails Patients With CLL
Not exactly an optimistic report.
Dr James Gerson, MD, - "Not a lot is known as to what happens in...
The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden
Details about CAR-T procedure and side effects.
CAR (T cells and natural killer cells) constitutes...
Related Posts
- The current status and challenges of CAR-T therapy in CLL
- Zanubrutinib-Gazyva Shows Promise for CLL/SLL
- Diptheria Immunotoxin Effectively Targets B-Cell Malignancies - Phase 1 trial of DT2219
Scientists hail autoimmune disease therapy breakthrough - implications for CLL patients?- CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction
